Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy by Miller, Bryan W. et al.
Research Article
Targeting the LOX/hypoxia axis reverses many of
the features that make pancreatic cancer deadly:
inhibition of LOX abrogates metastasis and
enhances drug efficacy
Bryan W Miller1,†, Jennifer P Morton1,†, Mark Pinese2,†, Grazia Saturno3,†, Nigel B Jamieson4,
Ewan McGhee1, Paul Timpson2, Joshua Leach1, Lynn McGarry1, Emma Shanks1, Peter Bailey5,
David Chang5, Karin Oien5, Saadia Karim1, Amy Au1, Colin Steele1, Christopher Ross Carter4,
Colin McKay4, Kurt Anderson1, Thomas R Jeffry Evans1,5, Richard Marais3, Caroline Springer6,†,
Andrew Biankin5,†, Janine T Erler7,†,* & Owen J Sansom1,†,**
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading
causes of cancer-related mortality. Despite significant advances
made in the treatment of other cancers, current chemotherapies
offer little survival benefit in this disease. Pancreaticoduodenecto-
my offers patients the possibility of a cure, but most will die of
recurrent or metastatic disease. Hence, preventing metastatic
disease in these patients would be of significant benefit. Using
principal component analysis (PCA), we identified a LOX/hypoxia
signature associated with poor patient survival in resectable
patients. We found that LOX expression is upregulated in
metastatic tumors from Pdx1-Cre KrasG12D/+ Trp53R172H/+ (KPC)
mice and that inhibition of LOX in these mice suppressed metasta-
sis. Mechanistically, LOX inhibition suppressed both migration and
invasion of KPC cells. LOX inhibition also synergized with gemcita-
bine to kill tumors and significantly prolonged tumor-free survival
in KPC mice with early-stage tumors. This was associated with
stromal alterations, including increased vasculature and decreased
fibrillar collagen, and increased infiltration of macrophages and
neutrophils into tumors. Therefore, LOX inhibition is able to
reverse many of the features that make PDAC inherently refractory
to conventional therapies and targeting LOX could improve
outcome in surgically resectable disease.
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Introduction
Pancreatic cancer is one of the leading causes of cancer-related
death in the UK with around 7,000 cases being diagnosed every year
(Mukherjee et al, 2008). Pancreatic ductal adenocarcinoma (PDAC)
is almost universally lethal. Aggressive invasion and early metasta-
ses are characteristic of the disease, such that 80–90% of patients
have surgically unresectable disease at the time of diagnosis
(Giovinazzo et al, 2012). The majority of patients who are selected
to undergo potentially curative resection for small, localized lesions
almost inevitably develop recurrent or metastatic disease (Yeo et al,
2002), presumably due to the presence of undetected micro-metasta-
ses at initial diagnosis. Adjuvant (post-operative) chemotherapy can
improve outcome despite the modest anti-tumor efficacy of these
agents (Neoptolemos et al, 2004; Stocken et al, 2005). Nevertheless,
overall survival remains disappointing with most patients develop-
ing local recurrence or extra-pancreatic metastasis within 2 years
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(Giovinazzo et al, 2012). Hence, there is a requirement for biomar-
kers to predict/prognosticate those patients that do not succumb to
early recurrence post-resection and identify potentially targetable
pathways that may be associated with poor prognosis. This has
been made even more important by recent sequencing studies of
pancreatic cancer, which have found PDAC to be very complex and
contain multiple low-frequency mutations of unknown functional
significance. Moreover, none of the major mutations (KRAS, TP53,
SMAD4 and INK4A) currently confer treatment opportunities.
Importantly, these surgically resectable patients who die of recur-
rent metastatic disease represent a set of patients where suppression
of metastasis (either prevention or suppression of growth of micro-
metastasis) may be a realistic therapeutic option and trials are
underway to test whether SRC inhibitors may be beneficial in this
patient set.
A characteristic feature of PDAC is the highly desmoplastic stro-
mal microenvironment. This stroma consists of immune cells, colla-
gen and fibronectin laid down by fibroblasts and stellate cells (Chu
et al, 2007). In addition to contributing to disease progression, and
promoting tumor growth and invasion, recent studies suggest that
the stroma also limits drug delivery to tumor cells, partly explaining
the profound resistance of pancreatic tumors to systemic chemother-
apy agents (Olive et al, 2009). This situation is made worse by a
very poor tumor vasculature which may also limit drug access to
tumors (Olive et al, 2009). Consistent with this, a number of studies
have shown that potential stromal markers such as S100A2 and A4
have prognostic value in patients with resected PDAC (Jamieson
et al, 2011). More recently, there has been great interest in the role
of the enzyme lysyl oxidase (LOX) in driving metastasis in epithelial
cancers such as breast and colorectal cancer (Payne et al, 2005;
Baker et al, 2011; Cox & Erler, 2013). LOX is a copper-dependent
enzyme which cross-links collagen and elastins to drive tissue stiff-
ness (Barker et al, 2012). It has previously been shown to be
induced by hypoxia-inducible factor 1a (HIF1a) and can function
upstream of the SRC/FAK tyrosine kinases (Payne et al, 2005; Erler
et al, 2006; Baker et al, 2011, 2013). These studies suggest that LOX
inhibition will have the potential to suppress metastasis rather than
causing regression of established tumors (Cox et al, 2013; Cox &
Erler, 2014), consistent with observations using SRC inhibitors in
cancer cell lines and mouse models (Morton et al, 2010a). Addition-
ally, LOX has been reported to have direct effects on cancer cells
themselves through regulation of senescence (Wiel et al, 2013).
There is a plethora of evidence that inflammation is tumor
promoting in pancreatic cancer. Pancreatitis leads to increased risk
of PDAC, while cerulein promotes acinar-to-ductal metaplasia and
disease progression (Guerra et al, 2007; Rhim et al, 2012).
However, it is also clear that the presence of leukocytes such as
neutrophils within tumors is often associated with a good prognosis
in many different cancer types including pancreatic cancer (Caruso
et al, 2002; Schaider et al, 2003; Jamieson et al, 2012). Thus far,
there are no mechanistic data to explain this phenomenon, nor is it
known how the desmoplastic “stiff” stroma would affect the ability
of leukocytes to penetrate tumor tissue.
Given the complex interplay between the tumor and the
stroma, modeling therapies in these systems require immunocom-
petent mice that develop tumors that closely recapitulate human
disease. Genetically engineered mice carrying the common muta-
tions that occur in PDAC rapidly generate invasive and metastatic
disease (Morton et al, 2010b). Therefore, these can serve as excel-
lent models in which to test therapies aimed at targeting the
stroma and assess the impact of the mutations that occur in
pancreatic cancer upon the stroma, invasion and metastasis. Our
and others’ previous studies have shown that the accumulating
mutant p53 (p53R172H) has gain-of-function properties over loss-of-
function mutations (Olive et al, 2004; Jackson et al, 2005; Adorno
et al, 2009; Morton et al, 2010b). Consistent with this, we and
others have previously found that mice expressing p53R172H
display a far higher frequency of liver metastasis than mice with
loss of p53 function (Morton et al, 2010b; Weissmueller et al,
2014). However, it has been reported that mice carrying loss
of function of p53 and INK4 loss alongside KrasG12D targeted to
the pancreas develop adenocarcinoma that metastasizes to the
liver (Bardeesy et al, 2006). As yet, most work has focused
on how mutant p53 facilitates cell autonomous migration and
invasion and has not examined whether it affects tumor–stromal
interactions.
While the majority of studies had suggested that targeting the
stroma may be a promising therapeutic option in this disease, recent
studies have shown dramatically different results. Here, targeted
sonic hedgehog depletion or myofibroblast disruption has reported
decreased survival in mouse models (Lee et al, 2014; Ozdemir et al,
2014; Rhim et al, 2014).These studies suggest that thinking of the
tumor stroma simply as a tumor-promoting entity needs to be
re-evaluated and it will be very important to understand which
elements of the stroma drive the chemoresistance and early progres-
sion of pancreatic cancer, and which act to constrain the tumor. It
should be noted that these studies also showed that subsequent co-
targeting with either anti-angiogenesis or immunotherapy could
then lead to significant tumor regression.
In this study, we identify LOX, driven by mutant p53, as an
important therapeutic target in pancreatic cancer, inhibition of
which causes tumor necrosis in combination with gemcitabine.
Importantly, the LOX–hypoxia axis defines the poor prognosis of
surgically resectable cancers and can explain many of the features
that contribute to making PDAC inherently refractory to conven-
tional cytotoxic chemotherapy. Most importantly, inhibition of LOX
can reverse most of these features, suggesting that this may be a
promising therapeutic approach.
Results
LOX/hypoxia marks poor prognosis in patients with
resected PDAC
To elucidate the key components that contribute to poor prognosis
in patients with PDAC, a gene signature analysis was performed on
the transcriptome of 73 PDACs (Biankin et al, 2012). From this, a
single signature was identified (called PC-1) that following cross-
validation could predict survival in the discovery cohort (Fig 1A).
PC-1 could be split into two gene sets: a hazardous set of 321 tran-
scripts, for which increased expression was associated with poor
prognosis, and a protective set of 238 transcripts, for which
increased expression was beneficial. To identify potential biological
processes underlying the survival signature, we tested the hazard-
ous and protective sets of PC-1 for overlap against the MSigDB
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gene set database (Subramanian et al, 2005). We observed that the
hazardous subset of PC-1 showed significant overlap with numerous
hypoxia signatures, and the protective subset was linked to lympho-
cyte and antigen presentation signatures (Supplementary Table S1).
We confirmed that high expression of a hypoxia signature correlated
with poor prognosis (Fig 1B). From this hypoxia signature, we
selected LOX for further analysis given we wished to investigate
factors that could modulate the stroma that are targetable, its previ-
ous association with the mesenchymal subtype and reports of its
involvement in metastasis in breast and colon cancer (Payne et al,
2005; Baker et al, 2011). We examined overall survival in terms of
the expression of LOX using an expanded APGI cohort of 266
patients (Chou et al, 2013). Expression of LOX correlated with
patient survival (Fig 1C), and we confirmed this correlation using
multivariate analysis (Supplementary Table S2). We next looked in
our Glasgow cohort of patients where 47 patients have been profiled
and once again high LOX expression correlated with a poor progno-
sis (Fig 1D). Moreover, LOX was 1 out of only 5 probe sets that
overlapped between the Glasgow (Jamieson et al, 2011) cohort and
the Collisson (Collisson et al, 2011) signatures of poor prognosis in
pancreatic cancer (the others being S100A2, TWIST, NT5E and
PAPPA) (Supplementary Fig S1). Additionally, high expression of
further LOX family members (LOXL1, 2, 3 and 4) were found to be
associated with poor prognosis in the Glasgow data set (Supplemen-
tary Fig S1B–E). Taken together, and given the reproducibility
across multiple patient cohorts, these findings argued for a signifi-
cant role for LOX expression as a determinant of poor survival in
pancreatic cancer.
A B C
D E F
Figure 1. LOX/hypoxia marks poor prognosis in resectable PDAC.
A Kaplan–Meier analysis showing cases from the Australian cohort (n = 73) delineated on the basis of expression of a set of hazardous genes, termed PC-1. Patients
with the highest expression had a significantly poorer prognosis (red line, median survival: 11.6 months) compared with those patients with the lowest expression
(blue line, median survival: 34.4 months, P = 0.01). The black line shows those with medium expression.
B Kaplan–Meier analysis showing that cases in the Australian cohort that fell in the highest quartile of a hypoxia signature (red line, median survival: 11.4 months)
have significantly decreased survival compared with those in the lowest quartile (blue line, median survival: 25.2 months; P = 0.03).
C Kaplan–Meier analysis showing that cases in the APGI cohort (n = 266) with high LOX expression above the 3rd quantile (red line) have significantly decreased survival
compared to those with low expression below the 1st quantile (blue line).
D Kaplan–Meier analysis showing that cases in the Glasgow cohort with high LOX expression (red line, n = 24) have significantly decreased survival compared with
those with low expression (blue line, n = 23; P = 0.005).
E Kaplan–Meier analysis showing that fibrillar collagen is significantly associated with reduced survival in human PDAC (20 months vs. 28.3 months, P = 0.033).
F Mean decay distance of the second harmonic generation (SHG) signal emitted by human PDAC-associated collagen. Mean decay distance is represented by boxplots
showing the second and third quartile of the data with the whiskers indicating the maximum and minimum data points. Outliers are indicated by individual
markers. Stage T3 tumors have a higher collagen mean decay distance score compared with Stage T2 tumors (P = 0.02). Lymph node-positive tumors have a higher
collagen mean decay distance score vs. lymph node-negative tumors (P = 0.047). Tumors showing vascular invasion have a higher collagen mean decay distance
score than non-vascular invasive tumors (P = 0.037).
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As LOX is associated with regulation of collagen cross-linking,
we assessed the status of fibrillar collagen in human PDAC. Using
multiphoton microscopy, we analyzed the second harmonic reso-
nance signal of collagen in a human pancreatic tissue microarray
(TMA) consisting of 80 patients. Second harmonic generation (SHG)
imaging of collagen has been used previously to identify collagen
“signatures” in mammary tumors, which may impact on the ability
of cancer cell migration (Provenzano et al, 2006, 2009). In our
study, we found that fibrillar collagen was significantly associated
with reduced survival (20 months vs. 28.3 months, P = 0.033)
(Fig 1E). Further, we showed that fibrillar collagen was significantly
associated with increased tumor stage, lymph node spread and
vascular invasion (Fig 1F). This suggested that the generation of
fibrillar collagen may be important in PDAC disease progression and
that the inhibition of cross-linking needed to generate collagen fibers
via LOX inhibition may be important therapeutically.
In order to further investigate this, we used immunocompetent,
autochthonous genetically engineered mouse models of PDAC,
which are initiated by targeting Kras mutation to the murine
pancreas using the Pdx1-Cre transgene. Without the addition of
cooperating mutations, only one-third of Pdx1-Cre KrasG12D/+ mice
develop PDAC by 500 days (Hingorani et al, 2003). However, when
p53 is additionally targeted by deletion or mutation, mice rapidly
develop invasive adenocarcinoma with a median latency of between
120 and 180 days (Hingorani et al, 2005) and we have previously
found that p53 mutation, but not loss, could drive metastasis in this
model (Morton et al, 2010b). In order to characterize the gene
expression changes that underlie metastatic disease, we carried out
microarray analysis of tumors driven by Kras mutation and muta-
tion of one copy of p53 or deletion of p53. To address whether tran-
scriptional changes observed in pancreatic cancer patients were
reflected in our mouse models, we applied loading values obtained
from the PC-1 human tumor signature to our mouse microarray
data sets (http://www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?acc=
GSE67358). This allowed us to derive risk scores for each individual
mouse transcriptome. While the majority of mice that had non-
metastatic tumors had negative risk scores, 100% of KPC mice that
developed metastatic disease had positive risk scores (Fig 2A, top).
Of the gene expression changes observed between metastatic and
non-metastatic tumors, multiple members of the LOX family were
overexpressed in metastatic disease (Fig 2A, bottom).
LOX is required for mutant p53-driven invasion
Given that our data suggest a role for LOX in mutant p53-driven
metastatic PDAC, we decided to address the consequences for cell
migration and invasion, of manipulating LOX expression in PDAC
cell models. For this, we used both KPC cell lines and cells derived
from Pdx1-Cre KrasG12D/+ p53flox/+ (KPflC) tumors. Initially, to
assess whether LOX expression was required for invasion, we used
siRNA to knockdown LOX expression and measured migration of
KPC cells through a Matrigel matrix (Supplementary Fig S2A). Loss
of LOX expression significantly impaired KPC cell migration, and
this could be rescued by recombinant LOX protein. Inhibition of
LOX in KPC cells led to a reduction in SRC phosphorylation (Supple-
mentary Fig S2B), and we confirmed that low doses of the SRC
inhibitor dasatinib resulted in a slowing of wound healing (Supple-
mentary Fig S2C). Given our previous data showing a requirement
for SRC in KPC cell invasion (Morton et al, 2010a), this suggests
that the pro-migratory effects of LOX could be mediated at least in
part by SRC activation. We confirmed that LOX knockdown in
human Panc-1 cells had similar effects on migration (Supplementary
Fig S2D). We have previously shown that the ability of mutant p53
cells (and not p53-deleted cells) to invade in vitro correlates well
with the ability of these cells to metastasize in vivo (Fig 2B). Analy-
sis of the expression of LOX family members in these cell lines
showed a clear increase in the expression of LOX and LOX family
members in cell lines carrying mutant but not loss-of-function p53,
consistent with our microarray analyses (Supplementary Fig S2E).
Thus, we carried out stable knockdown of LOX in KPC cells using
shRNA and found this significantly reduced invasion of mutant p53
cells (Fig 2C; Supplementary Fig S2F). Conversely, overexpression
of LOX in p53 loss-of-function tumor cells promoted invasion of
these cells (Fig 2D).
In order to determine the effects of the modulation of LOX
expression in these cell models in vivo, we carried out a series of
allograft experiments. LOX knockdown slowed allograft growth of
KPC cells (Supplementary Fig S2G), while LOX overexpression
resulted in faster growth of KPflC cells (Supplementary Fig S2H).
In parallel, we also performed a functional screen on primary
cells from Pdx1-Cre KrasG12D p53R172H (KPC) metastatic tumors.
Overall, we found that 920 siRNAs reduced cell viability using a
Z-score threshold of -3 (Supplementary Table S3). A number of
these screen hits were extracellular matrix components, including
LOX, fibronectin and tenascin C. To enhance the predictive power
of our results, we overlaid the siRNA data with microarray data and
components of the hazardous PC-1 signature. We identified 106 hits
using two of the approaches, and five that were hits in all three
analyses, one of which was LOX (Fig 2E). In order to confirm the
results of the screen, we knocked Lox down, observed a reduction
in the number of viable cells (Supplementary Fig S3A) and
confirmed that this effect could be rescued by recombinant protein
(Supplementary Fig S3B). Quantitation of live and dead cell
numbers by trypan blue exclusion showed that while Lox knock-
down led to a decrease in live cell number, this was not associated
with an increase in cell death (Supplementary Fig S3C). In response
to Lox knockdown, KPC cells expressed higher levels of fibronectin
mRNA and we found that the effects of Lox knockdown could be
enhanced by blocking integrin/fibronectin interaction using an a5-
integrin-blocking antibody (Supplementary Fig S3D). Thus, LOX
inhibition may also have impacts on tumor cells themselves that are
mediated by integrin and fibronectin. This suggests that in contrast
to the potentially oncogenic role of total depletion of tumor myofi-
broblasts (Ozdemir et al, 2014), blockade of collagen cross-linking
and LOX should not have tumor-promoting effects. These data from
cell models suggest that targeting LOX has the potential to inhibit
both cell invasion and growth at the secondary site, suggesting a
potential approach to target metastasis in vivo.
Treatment of KPC mice with LOX-blocking antibody in
combination with gemcitabine strongly suppresses
tumorigenesis
Thus far, all of our functional experiments with LOX inhibition were
not performed in any of the autochthonous models of PDAC that
faithfully recapitulate the human disease. Our prediction was that in
EMBO Molecular Medicine ª 2015 Cancer Research UK Beatson Institute
EMBO Molecular Medicine LOX inhibition in pancreatic cancer therapy Bryan W Miller et al
4
Published online: June 15, 2015 
this context, LOX inhibition was likely to have more of an impact,
as PDAC is well known to be a highly desmoplastic tumor with
marked levels of stromal collagen. Thus, in this environment,
expression of LOX protein should have a marked impact on the
surrounding stroma, driving the cross-linking of collagen and elastin
in the tumor microenvironment. To investigate the significance of
LOX overexpression in PDAC, we used a LOX function-blocking
antibody (Erler et al, 2006, 2009; Baker et al, 2011, 2013; Cox et al,
2013). This antibody is specific to LOX and does not recognize the
other members of the LOX family in Western blotting, while peptide
blocking studies and protein binding studies found no evidence of
binding to LOXL2 (Le et al, 2009; Baker et al, 2011, 2013; Cox et al,
2013). First, to justify that the antibody could modify LOX activity,
we investigated the ability of the antibody to block collagen cross-
linking in an ex vivo organotypic assay. In this assay, rat tail
collagen I is mixed with fibroblasts that secrete LOX protein. The
fibroblasts cross-link and contract the collagen and produce a matrix
that is often used to measure invasion ex vivo (Timpson et al,
2011a,b). Addition of the LOX-blocking antibody, but not the
isotype control antibody, to these cultures markedly reduced
fibrillar collagen (Fig 3A–C). Taken together with previous work
using this antibody, our data support the ability of this strategy to
block LOX activity.
To assess the functional importance of LOX in vivo, we next
treated KPC mice from day 70 with LOX-blocking antibody, gemcita-
bine, isotype control antibody with gemcitabine and LOX-blocking
antibody with gemcitabine. We chose this timepoint for these stud-
ies since our aim is to mimic surgically resectable disease without
evidence of overt, macroscopic metastases. Moreover, in the recent
study using hedgehog inhibitors showed that treatment at a slightly
A
D
B C
E
Figure 2. LOX expression is required for invasion in a mutant p53-driven model of PDAC.
A PC-1 signature is predictive of metastatic disease in mouse models of pancreatic cancer. Log-transformed expressions of signature transcripts from mouse tumor
microarrays were mean-centered across samples and scaled to unit variance. These values were then multiplied by the matching loading values from the PC-1
signature and summarized for each sample across all transcripts to yield the risk score for that sample.
B Inverted invasion assays were performed with PDAC tumor cell lines from KPC and KPflC mice. Tumor cell lines bearing mutant p53R172H (KPC) invade significantly
further than tumor cells with deletion of 1 copy of p53 (KPflC) (P ≤ 0.01). Data are shown as the average of four wells + SEM.
C Introduction of shRNA targeting Lox into KPC tumor cells significantly inhibits invasion (P ≤ 0.01 by unpaired Student’s t-test). Data are shown as the average of four
wells + SEM.
D Introduction of exogenous LOX into KPflC tumor cells significantly promotes invasion (left panel, P ≤ 0.01 by unpaired Student’s t-test). LOX expression was assessed
by immunoblotting (right panel). Columns indicate the mean of four well and error bars indicate SEM.
E Integration of heterogeneous data sets identifies LOX as a therapeutic target in pancreatic cancer. Components of the hazardous PC-1 signature are overlaid with
genes found to be overexpressed in a microarray and hits that cause a reduction in viable cell number in an RNAi functional screen. Overlap is shown as a
proportional Venn diagram.
Source data are available online for this figure.
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earlier stage of disease revealed the tumor-promoting effects of
hedgehog inhibition which were not seen in mice with late-stage
disease (Rhim et al, 2014). This is important as the human hedge-
hog inhibitor trials stopped due to concerns over disease accelera-
tion. At this 70-day timepoint, mice have widespread advanced
pancreatic neoplasia (Hingorani et al, 2005; Morton et al, 2010a).
Cohort size was based on our previously reported work where we
have shown that treatment with dasatinib at this timepoint reduced
metastasis without affecting primary tumor growth (Morton et al,
2010a). In addition, tumors in these mice are resistant to gemcitabine
treatment. This contrasts with chemoprevention experiments we
have conducted where gemcitabine treatment from 5 to 6 weeks
suppresses pancreatic tumorigenesis (Supplementary Fig S4A).
In comparison with previous cohorts and control-treated KPC
mice, we saw a significant slowing of tumorigenesis in mice treated
with the combination of LOX antibody and gemcitabine, with a
median survival of 226 days, compared with 153 days in mice
treated with either gemcitabine or gemcitabine + isotype control
antibody (Fig 3D, Table 1, P = 0.014). Interestingly, symptoms of
drug toxicity due to long-term gemcitabine treatment meant that six
A
D E F
G H I
B C
Figure 3. LOX inhibition, in combination with gemcitabine, extends pancreatic cancer-free survival in KPC mice.
A Representative fluorescence images showing the SHG signal from cross-linked collagen in untreated, LOX antibody-treated or isotype control-treated organotypic
cultures of primary fibroblasts and rat tail fibrillar collagen I.
B Chart showing the percentage of cross-linked collagen by depth, based on SHG signal, in organotypic matrices treated as indicated. Error bars indicate SEM.
C Barchart showing total cross-linked collagen in organotypic matrices treated as indicated. The experiment was performed in triplicate with three different zones
imaged for 80 lm, at 2.5-lm sections each. Data are shown as total pixels  SEM.
D Kaplan–Meier (non-parametric) survival curve showing significantly extended tumor-free survival of KPC mice treated with LOX antibody (1 mg/kg i.p., twice
weekly) + gemcitabine (100 mg/kg i.p., twice weekly) (green line, n = 17), compared with gemcitabine  isotype control antibody-treated mice (blue line, n = 22,
P = 0.014) or LOX antibody alone (red line, n = 9). Treatment was initiated when mice were 70 days old (randomization was not used when recruiting the mice)
and the mice were treated twice weekly. Censored mice did not develop PDAC.
E H&E-stained section of PDAC harvested from LOX + gemcitabine-treated KPC mouse. Note necrosis.
F Boxplot showing quantification of necrosis in H&E sections of PDACs harvested from these mice, as indicated. At least 30 fields of view from at least five mice per
cohort were scored.
G–H H&E-stained sections of PDAC harvested from LOX + gemcitabine-treated KPC mice. Note stromal collapse (G) and marked dilation of blood vessels (H).
I Representative H&E image showing a section of PDAC harvested from a control-treated KPC mouse.
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of these mice were free of pancreatic tumors at the time of sacrifice,
including two mice that were > 200 days at the time of sacrifice.
Moreover, a significant reduction in metastasis formation was
observed in LOX + gemcitabine-treated mice (2/13 mice), while a
complete absence of metastasis was observed in the mice treated
with LOX-blocking antibody (Table 1). Similar to previous studies,
mice treated with gemcitabine alone or gemcitabine + isotype
control antibody developed metastasis in 80% of cases (Table 1).
As we have previously observed (Morton et al, 2010a), an absence
of metastasis alone was not sufficient to increase survival in the
LOX-treated mice as they still became sick of primary tumor burden.
To understand the mechanism of action of the LOX-blocking anti-
body and the increased benefit with gemcitabine, we next analyzed
the tumor and stroma from these mice. Histological examination of
these tumors revealed a marked and significant increase in necrosis
in the tumors treated with the combination of LOX-blocking anti-
body and gemcitabine, along with stromal changes and dilation of
blood vessels (Fig 3E–H). In contrast, virtually no necrosis was
observed in control tumors (Fig 3I). Moreover, a marked leukocyte
infiltration was also observed and immunohistochemical staining
for both macrophages (by F4/80 IHC, left panels Fig 4A, quantita-
tion Fig 4B) and neutrophils (MPO IHC, 2nd from left panels Fig 4A,
quantitation Fig 4C). Another hallmark of tumors arising in the KPC
model is a poor vasculature and this was again subverted, with a
clearly increased number of “open” blood vessels in the KPC mice
treated with LOX-blocking antibody  gemcitabine (CD31 IHC, 2nd
from right panels Fig 4A), although interestingly, vessel number
was elevated in all treatment groups (Fig 4D). Tenascin C is a stro-
mal marker previously reported to be induced in pancreatic cancer
and has been implicated in metastasis in other cancer models (Juuti
et al, 2004; Oskarsson et al, 2011). We therefore examined whether
there was a correlation between LOX inhibition and tenascin C
expression and found a complete absence of stromal staining in LOX
antibody + gemcitabine-treated mice (Fig 4A right panels). More-
over, when we further examined the specific relationships between
stromal markers such as LOX and tenascin C, we found a significant
correlation in human PDAC (Fig 4E). Interestingly, there was no
significant difference in levels of proliferation, or apoptosis (Supple-
mentary Fig S4B and C) following treatment with LOX, gemcitabine
or LOX and gemcitabine combination. This suggested that although
LOX inhibition can have an effect on the tumor cells in culture, this
was not sufficient to affect tumor proliferation in vivo. As one of the
consequence of LOX knockdown in vitro was an upregulation of
fibronectin (Supplementary Fig S3D), we tested the effect of further
increases in fibronectin and found this could rescue the inhibition
of proliferation caused by LOX inhibition (Supplementary Fig S4D).
In vivo, KPC tumors have very high levels of fibronectin (Supple-
mentary Fig S4E).
Importantly, when we performed picrosirius red staining to
examine the quantity of collagen in tumors from mice treated with
isotype control antibody, LOX antibody alone or in combination
with gemcitabine, we did not observe any significant differences
(Supplementary Fig S5A and B). However, when we examined the
degree of fibrillar collagen by SHG, as performed on the human
tissue microarray earlier, we found that tumors in mice treated with
LOX-blocking antibody + gemcitabine had significantly less fibrillar
collagen when compared with mice treated with gemcitabine alone
(Supplementary Fig S5A and C).
Interestingly, we saw no evidence of increased gemcitabine pene-
trance into the tumor when mice were treated with LOX antibody
and gemcitabine compared with isotype control and gemcitabine
(Supplementary Table S4). Thus, combining LOX Ab with gemcita-
bine does not improve survival by increasing drug penetration.
Instead, we would suggest that the effects on the stroma result in
the loss of key microenvironment-mediated pro-survival signals that
would normally drive resistance to therapy. We also observed that
KPC cells grown on collagen were less sensitive to gemcitabine
treatment than those grown on an uncoated plate (Supplementary
Fig S5D). Taken together, our data clearly show that the LOX-block-
ing antibody, when administered in combination with gemcitabine,
can reverse many of the hallmarks of PDAC that are thought to yield
resistance to treatment and most pertinently here, it can reverse
the two pathways that are conferring poor prognosis in PDAC
(hypoxia/LOX).
LOX inhibition at late-stage disease
Mechanistically, our data were suggestive that LOX-mediated colla-
gen cross-linking is a pro-survival and metastatic factor in PDAC. If
this was the case, one would predict that LOX inhibition would have
a more marginal effect in late-stage disease due to tumours already
having significant levels of cross-linked collagen. Therefore, we
treated mice with a palpable tumor burden with the LOX-blocking
antibody alone and in combination with gemcitabine.
As predicted, treatment with LOX-blocking antibody and gemcit-
abine did not have a significant effect on survival with mice with
late-stage disease, although fewer of these mice had metastasis
following treatment (Supplementary Fig S6A). We also did not
observe alterations of gemcitabine uptake into the tumor or changes
in collagen levels (Supplementary Fig S6B and D). Importantly,
Table 1. Metastatic burden in LOX Ab-treated PDAC-bearing mice.
Treatment Median survival
Metastatic burden
Metastases Liver Lung Diaphragm Peritoneal
Gem 126 days 3/3 2/3 0/3 1/3 1/3
IgG + Gem 153 days 8/11 5/11 1/11 1/11 1/11
LOX Ab 136 days 0/8 0/8 0/8 0/8 0/8
LOX + Gem 226 days 2/13 2/13 2/13 2/13 0/13
Table showing metastatic burden in PDAC-bearing mice treated as indicated. LOX Ab vs. Gem, P = 0.0106 (Chi2 + Yates’ correction); LOX + Gem vs. IgG + Gem,
P = 0.0154 (Chi2 + Yates correction). LOX, lysyl oxidase; Ab, antibody; Gem, gemcitabine.
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many of the alterations we observe in mice treated from an earlier
stage were not recapitulated in mice with late-stage disease; namely,
no significant changes were found in blood vessel number, necrosis,
tenascin C levels or macrophage infiltration (Supplementary Fig S6C
and E–G). We did observe alterations in immune cell infiltration
with decreased neutrophil infiltration and increased T-cell infiltra-
tion (Supplementary Fig S6H and I). These data are consistent with
our model that anti-LOX therapies work by modulating collagen
cross-linking.
Discussion
Pancreatic ductal adenocarcinoma has a dire prognosis with 85% of
patients presenting with tumors that are unresectable. The current
standard of care therapy for these patients only prolongs survival to
a median of 6 months. Even patients that undergo potentially cura-
tive resection almost inevitably develop metastatic disease. Thus,
new treatment options are required both for patients with resectable
disease and for patients with advanced disease.
In this study, we show that a functional axis can define survival
in patients that undergo pancreaticoduodenectomy and that a
“hypoxia/LOX” signature and high levels of fibrillar collagen are
associated with poor prognosis. This suggests that fibrillar collagen
(potentially quantifiable by elastography using endoscope-guided
ultrasound in the clinic) and LOX expression have potential as prog-
nostic markers in pancreatic cancer. We also show that manipula-
tion of a key element of this hypoxia/LOX signature can reverse
most of the features of the axis and leads to a remarkable increase
in survival of KPC mice. This model can be seen a gold standard for
A
B C D E
Figure 4. Enhanced leukocyte infiltration and stromal markers in LOX antibody-treated mice.
A Outer left panels: Immunohistochemical analysis of macrophage infiltration (by F4/80 staining) in tumors from isotype control + gemcitabine-treated KPC mice vs.
LOX antibody + gemcitabine-treated KPC mice. Inner left panels: Immunohistochemical analysis of neutrophil infiltration (by MPO staining) in tumors from isotype
control + gemcitabine-treated KPC mice vs. LOX antibody + gemcitabine-treated KPC mice. Inner right panels: Immunohistochemical analysis of tumor vasculature
(by CD31 staining) in tumors from isotype control + gemcitabine-treated KPC mice vs. LOX antibody + gemcitabine-treated KPC mice. Outer right panels:
Immunohistochemical analysis of tenascin C expression in tumors from isotype control + gemcitabine-treated KPC mice vs. LOX antibody + gemcitabine-treated
KPC mice.
B–D Plots showing quantification of macrophage infiltration (B), neutrophil infiltration (C) and tumor vasculature (D) in tumors from KPC mice treated as indicated. At
least 30 fields of view from at least four mice per cohort were scored, and scoring was conducted blind. P-values were calculated using Mann–Whitney U-test and
median is indicated by horizontal lines.
E Correlation of LOX protein with tenascin C expression in 47 cases of PDAC (Spearman’s rho correlation coefficient = 0.61; P < 0.0001).
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pancreatic cancer treatment, as it recapitulates many of the clinical
features of the human disease including its poor response to gemcit-
abine (and most other cytotoxic chemotherapy agents), and mice
develop invasive and metastatic disease.
One striking feature of LOX inhibition in the KPC model was stro-
mal alterations that were associated with increased tumor vasculari-
zation, immune cell infiltration and drug efficacy. Recently, there
has been considerable interest in the role of tumor–stromal interac-
tion in pancreatic cancer. Previous studies showed that targeting the
stroma with inhibitors of Shh signaling led to increased (Olive et al,
2009) or decreased (Rhim et al, 2014) survival in PDAC mouse
models, depending on the treatment regime and mouse model used.
A further study found that targeting stroma through myofibroblast
deletion also led to decreased survival (Ozdemir et al, 2014). Stro-
mal alterations have been associated with increased vascularization
of tumors (Olive et al, 2009; Rhim et al, 2014) and increased effi-
cacy of gemcitabine (Olive et al, 2009) and anti-angiogenic therapies
(Rhim et al, 2014). For this reason, and in order to mimic surgically
resectable disease without overt metastases, we commenced treat-
ment of mice aged 70 days. Here, we saw no tumor acceleration at
any stage by LOX inhibition. It is interesting to note that in the
myofibroblast study, despite depletion of the myofibroblasts, neither
LOX levels nor collagen cross-linking was altered. This fits well with
our data where tumor cell secretes LOX and suggests it is the cross-
linking of collagen that is critical in defining the pro-tumorigenic
quality of the stromal. Thus, it becomes very important for the
community to ascertain the precise pro-tumorigenic elements of the
stroma and whether these are targetable, and in which patients, as
stromal targeting agents may affect tumor dynamics in different
ways depending on the tumor stage at diagnosis.
One of the challenges of the literature is the low number of prog-
nostic studies for which any overlap exists. One of the strengths of
the analyses presented here is that LOX is an indicator of poor prog-
nosis in both the Glasgow and Australian studies, as well as the
Collisson patient cohort (Collisson et al, 2011). Moreover, while
specific immune cell infiltration has been suggestive of a poor prog-
nosis (Mitchem et al, 2013), leukocyte infiltration per se can confer
a good prognosis in PDAC and in other cancer types (Caruso et al,
2002; Jamieson et al, 2012). One of the questions raised from our
work is “What is the direct relationship between LOX and immune
cell infiltration?” and we propose a model in which a tightly cross-
linked collagen matrix could block immune cell penetration into
tumors or inhibit chemotaxis. Importantly, loss of myofibroblasts in
PDAC was also shown to allow T-cell entry and immunotherapy
(Ozdemir et al, 2014). Consistent with this, we observe increased
T-cell infiltration into tumors during short-term treatment with anti-
LOX therapy, while macrophage and neutrophil infiltration was a
feature of longer-term treatment. Thus, future studies examining
combinatorial work with LOX inhibition and immunotherapy might
produce even more striking results.
Poor vascularization and “poor quality” vascularization in PDAC
have been shown previously and may be the predominant cause of
the hypoxia signature. There is a well-established link between
hypoxia and upregulation of LOX expression (Erler et al, 2006),
which only reinforces this situation and further impedes drug access
to tumors, although it has also previously been shown that LOX
activity can stimulate angiogenesis in colon cancer (Baker et al,
2013). One other key suggestion from this work is that this prognos-
tic signature could become a predictive signature to select patients
falling within the poor component of the axis and who would most
benefit from treatment with putative LOX inhibitors.
Our work may also yield new insights into how mutant p53 may
drive metastasis in PDAC. Our previous studies have shown key
roles for mutant p53 in driving the mechanics of invasion and
migration (integrin and met recycling) (Muller et al, 2009, 2013).
Here we show that mutant p53 within a tumor cell may also shape
the external tumor microenvironment. This may help to explain
our previous observations that mutant p53, but not loss-of-function
p53, leads to PDAC metastasis in this mouse model (Morton et al,
2010b). The idea that mutant p53 in tumor cells may help shape
their microenvironment also aligns with our previous work which
found that RhoA activity was localized at the tips of mutant p53-
expressing pancreatic cancer cells during invasion (Timpson et al,
2011b). Mechanistically, this may also be due in part to a reduction
in SRC activity, which we have previously shown to be important
for metastasis in this system and has been shown to be down-
stream of LOX in many other systems (Morton et al, 2010a).
Indeed, we previously showed that LOX signals through SRC to
increase colon cancer tumor cell proliferation, invasion and metas-
tasis (Baker et al, 2011). It is interesting to note that in vitro, we
also observe cell-intrinsic anti-proliferative effects of LOX knock-
down. This may explain the suppression of metastasis in mice
treated with LOX antibody alone. Cells in culture may be subjected
to similar stresses as metastasizing tumor cells, and in this situa-
tion, cell matrix proteins such as LOX could support cell survival
and proliferation.
Very recently, it has been announced that LOXL2-blocking anti-
bodies did not improve outcome in a phase two trial in advanced
pancreatic cancer (Benson et al, 2014). This is consistent with our
data as the LOX-blocking antibody was unable to suppress pancre-
atic cancer in mice with advanced disease. This correlated with the
inability of the antibody to reverse the collagen cross-linking at this
stage. It should be noted that to our knowledge experiments with
LOXL2 antibodies have not been performed in autochthonous
models and it would be of interest to see whether LOXL2-blocking
antibodies would suppress metastasis.
In summary, we believe we have identified a crucial axis in
PDAC that could be exploited as a therapeutic target. This would
strongly support further development of LOX inhibitors for PDAC
and the continued investigation of other approaches to target the
tumor microenvironment in this disease. We propose that LOX
inhibitors could potentially improve disease-free and overall
survival when administered in combination with gemcitabine (stan-
dard of care) following resection of PDAC in selected patients, and
could potentially enhance the efficacy of gemcitabine-containing
chemotherapy regimens in patients with advanced, inoperable
disease, thereby improving objective responses and overall survival.
Materials and Methods
Identification of a hypoxia-related survival signature
RNA of bulk primary tumor specimens from 73 patients with
confirmed PDAC was arrayed on Illumina HumanHT-12 v4
microarrays (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
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GSE50827). Samples were from patients recruited into the Austra-
lian Pancreatic Cancer Genome Initiative (Biankin et al, 2012).
Arrays were processed using the R package lumi (R version 2.15.1,
lumi version 2.8.0) with VST transformation and RSN normaliza-
tion, and batch effects were removed using ComBat (Johnson et al,
2007). Probes were variance-filtered, collapsed into per-gene tran-
scripts by selecting the highest variance probe for each gene and
filtered for univariate survival association using a 1,000,000-round
permutation test based on the FAST statistic (Gorst-Rasmussen &
Scheike, 2012). Transcripts were selected if their local FDR as esti-
mated by the Strimmer method (Strimmer, 2008) was less than
0.15. The expression of survival-associated transcripts was decom-
posed into metagenes by PCA, and the ability of each principal
component to predict survival was assessed based on the values
calculated by leave-one-out cross-validation applied to the full meta-
gene discovery pipeline. Gene set over-representation analysis was
performed using hypergeometric tests against MSigDB classes c1, c2
and c3; sets were called significant if their Benjamini–Yekutieli FDR-
corrected P-values (Benjamini & Yekutieli, 2001) were less than
0.05.
Scoring gene expression data for a hypoxia signature
A hypoxia meta-signature was generated by first selecting MSigDB
v3.0 c2 gene sets with names containing the term “HYPOXIA.”
Twenty-two gene sets were identified, containing 1,377 genes. Fifty-
five genes were represented in more than 20% of the hypoxia sets
and formed a hypoxia meta-signature. Samples from the APGI
microarray cohort were scored on this meta-signature by PCA:
Mean-centered gene expression measurements for only the meta-
signature genes were fit by PCA, and the loadings of the first princi-
pal component were used as hypoxia scores. To link increased
values of the hypoxia score with increased hypoxia, scores were
inverted if necessary, so that the rotation of VEGFA mRNA, a known
hypoxia-induced transcript present in the meta-signature, was
positive.
Glasgow cohort gene expression analysis
Macrodissected fresh-frozen pancreatic tissue samples were used:
47 PDACs were obtained from patients undergoing pancreaticoduo-
denectomy at the West of Scotland Pancreatic Unit. Tissue was
collected prospectively with local ethical approval, fully informed
consent, pathology assessment and validation. Only histologically
proven PDACs were included. Complete clinicopathological, follow-
up and recurrence data were available. RNA was isolated from
frozen tissue by standard TRIzol (Invitrogen) extraction according
to the manufacturer’s instructions. A nanodrop spectrophotometer
(NanoDrop Tech) quantified total RNA, whereas purity and integrity
was assessed on the Agilent 2100 Bioanalyzer with the RNA 6000
Nano LabChipVR reagent set (Agilent Technologies). Samples with
a RNA integrity number (RIN) above 7.0 were deemed suitable for
downstream analysis. Kaplan–Meier survival analysis was used to
analyze overall survival from the time of surgery. A log-rank test
was used to compare the length of survival between curves. Statisti-
cal significance was set at a P-value of < 0.05. All statistical analyses
were performed using SPSS version 19.0 (version 19.0. Armonk,
NY: IBM Corp.)
KPC cell transfection and high-throughput functional screens
Generation of KPC and KPflC primary cell models from transgenic
mice has previously been described (Morton et al, 2010b). Cells
were confirmed to be mycoplasma-free using an in-house myco-
plasma testing service. All siRNAs were siGENOME smartpools
and were used at a concentration of 25 nM (Thermo Fisher Scien-
tific). Transfection of KPC cells was carried out with Dreamfect
Gold (Oz Bioscience), and transfection of Panc-1 cells was carried
out with Lipofectamine 2000 (Qiagen). Cell viability was measured
by the absorbance 72 h after transfection using Cell Titer Blue
(Promega).
Lox expression was measured by quantitative RT–PCR (forward
primer: TCTTCTGCTGCGTGACAACC, reverse primer: GAGAAACCA
GCTTGGAACCAG) using GAPDH expression as a control (forward
primer: ACATCAAGAAGGTGGTGAAGCAGG, reverse primer: CCCT
GTTGCTGTAGCCGTATT C).
The following antibodies were used at the indicated concentra-
tions: LOX (Millipore ABT112, 1 in 500 dilution), SRC (Cancer
Research UK, 1 in 1,000 dilution) and YES1 pY537/SRC pY530
(Abgent AP3254a, 1 in 500 dilution). The a5-integrin-blocking anti-
body (mAb16) has been previously described (Muller et al, 2009).
Recombinant LOX protein was purchased from Cambridge Biosci-
ence (Origene TP313323).
For functional screens, 72 h following transfection, 50 lM
resazurin (Sigma) was added to the culture medium. Fluorescence
was measured using an Envision plate reader (Perkin Elmer).
Matrigel migration assays
Following 48 h transfection, wounds were made in the cell mono-
layer using a 96-well wound-making tool (Essen Bioscience). The
wounds were then overlaid with Matrigel and cell migration was
monitored using an Incucyte system (Essen Biosciences).
shLox and LOX overexpression in PDAC cells
KPC cells were transfected with 1 lg of MISSION pLKO.1-puro
empty vector control plasmid DNA (EV) or short hairpin targeting
LOX-containing plasmid (shLOX) (Sigma) using Lipofectamine (Invi-
trogen) for 48 h. Cells were then transferred into 2.5 lg/ml puromy-
cin (Invitrogen) containing medium for single-cell clone selection.
Two representative clones (shLOX C6 and shLOX C15) were then
chosen for further characterization.
KPflC cells were transfected with 1 lg of pCEF empty vector
control plasmid DNA (EV) or pCEF full-length LOX-containing
plasmid (LOX H1) using Lipofectamine (Invitrogen) for 48 h.
Cells were then transferred into 1 mg/ml G418 (Invitrogen)
medium for single-cell clone selection. One representative clone
(LOX H1) was chosen for further characterization. Similarly, one
additional KPflC overexpressing LOX clone and corresponding
empty vector control were generated by co-transfecting KPflC cells
with 1 lg of pLINK empty vector control plasmid DNA (EV) or
pLINK full-length LOX-containing plasmid (LOX C3) plus 0.1 1 lg
of PCDNA plasmid in order to confer cells the hygromycin resis-
tance. After 48 h, transfection cells were then transferred into
0.5 mg/ml hygromycin (Invitrogen) medium for single-cell clone
selection.
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Inverted in vitro invasion assays were carried out as previously
described (Arozarena et al, 2011).
Determination of collagen quantity and quality
Collagen second harmonic images were collected using a LaVision
Biotec Trim-scope equipped with a Coherent Chameleon Ti:Sapphire
femtosecond pulsed laser. An excitation wavelength of 890 nm was
used so that the SHG would be generated at a central wavelength of
445 nm and focused to the sample plane by a long working distance
of 20× (NA = 0.95) water immersion objective from Olympus. A
15-lm-deep stack was imaged over a region of 500 lm by 500 lm,
with at least six regions of interest per slide taken. Image analysis
was performed using ImageJ. To calculate the total area occupied by
collagen, a macro was written to let the user select a directory
containing the raw OME-TIFF stacks from the collagen SHG channel
and these were loaded in order and a maximum projection intensity
image was produced. An area calculator plugin was then run which
gave as the output the percentage area covered. A similar technique
was developed for performing the GLCM texture analysis. Firstly,
the user selected a directory containing the collagen stack images. A
maximum projection image was then produced and duplicated. The
duplicate image was then automatically thresholded to produce a
mask that was then applied to the original maximum projection
image. This removed the background noise bias introduced in the
GLCM analysis by selecting only the collagen SHG signal. The
masked image was then passed to the GLCM texture plugin, which
had been modified so that it could be operated in a nested loop for
varying pixel comparison distances and alternative directions of
comparison. The output of the plugin for each image was 100 rows
of the five texture parameters over each of four directions, so in
total 2,000 parameter values. These were saved as a text data file
for each image. When all the images in the directory were analyzed,
the data files were processed using a Matlab script that eventually
gave the mean of each texture parameter for each image. These
were then imported into Prism, where a double-exponential decay
model was fit to the data and the weighted mean decay distance for
each sample was calculated in Excel.
Glasgow cohort tissue microarray analysis
All patients gave written, informed consent for the collection of
tissue samples, and approval for collection was obtained from the
local research ethics committee. All cases underwent a standardized
pancreaticoduodenectomy. A total of 400 cores from a total of 80
PDAC resections with a full spectrum of clinicopathological features
were arrayed. At least five tumor cores (0.6 mm) and two from
adjacent normal tissue were sampled. Complete follow-up data were
available for all cases. Boxplots were used to show collagen score in
stage 2 vs. stage 3 tumors, lymph node-positive and lymph node-
negative tumors, and vascular invasion-positive and vascular inva-
sion-negative tumors, with these groups compared statistically using
a Mann–Whitney U-test. Kaplan–Meier survival analysis was used
to analyze the overall survival from the time of surgery. A log-rank
test was used to compare the length of survival between curves.
Statistical significance was set at a P-value of < 0.05. All statistical
analyses were performed using SPSS version 19.0 (version 19.0.
Armonk, NY: IBM Corp.).
Fibroblast-driven ECM remodeling and SHG quantification using
organotypic assay
Briefly, ~7.5 × 104/ml primary human fibroblasts were embedded in
a three-dimensional matrix of rat tail collagen I. Rat tail tendon
collagen solution was prepared by the extraction of tendons with
0.5 M acetic acid to a concentration of ~0.5 mg/ml. Detached, poly-
merized matrix (2.5 ml) in 35-mm petri dishes was allowed to
contract for approximately 8–12 days in complete media (DMEM,
supplemented with 10% FCS, Invitrogen) + control, isotype control
or LOX-blocking antibody (Timpson et al, 2011a,b). Using multipho-
ton imaging and a Ti:Sapphire femtosecond laser cavity (Coherent
Chameleon Ultra II), coupled into a LaVision Biotec Trim-scope scan
head, 890 nm excitation wavelength was used to collect SHG signal
(435  20 nm) from collagen from three separate matrices, within
three different zones as previously described (Samuel et al, 2011). A
z-section of 80 lm within the matrix was used at 2.5-lm intervals
to collect a 3D representation of the matrix ultrastructure as previ-
ously described (Samuel et al, 2011). ImageJ was used to calculate
ROI covered by SHG/fibrillar ECM signal per optical slice within the
volume, after conversion to a binary image based upon threshold
values. Columns, mean; error bars represent  SE for respective
treatment, P < 0.01 by unpaired Student’s t-test.
Allograft mouse models
All experiments were performed in accordance with the local ethical
review panel, the UK Home Office Animals Scientific Procedures
Act, 1986 and UKCCCR and NCRI guidelines (Workman et al,
The paper explained
Problem
Pancreatic cancer remains a highly deadly disease with current thera-
pies providing only marginal benefits to patients. Among the features
of pancreatic tumors that contribute to resistance to chemotherapies
is a highly desmoplastic stroma with high levels of cross-linked colla-
gen. While there has been considerable interest in targeting the
stroma of pancreatic tumors, there have been mixed reports of the
success of such approaches with some studies even reporting deleteri-
ous effects. Here we present evidence that lysyl oxidase (LOX) is a
therapeutic target that allows stroma targeting through reducing
collagen cross-linking.
Results
We identified that LOX and fibrillar collagen are predictive markers of
poor outcome in patients with resectable pancreatic tumors. Targeting
LOX in a transgenic model of pancreatic cancer led to an almost
complete abrogation of metastasis. When LOX was combined with
gemcitabine treatment, we saw evidence of a significant reduction in
fibrillar collagen in the primary tumor which was associated with
extensive stromal changes. We also observed greatly enhanced effi-
cacy of gemcitabine leading to a significant increase in mouse
survival.
Impact
Our study suggests that LOX is a therapeutic target in pancreatic
cancer with the potential to allow successful targeting of the stroma.
In contrast to other stromal targets reported, LOX inhibition proved
entirely beneficial in our studies and provides a potentially exciting
therapeutic approach in patients.
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2010). Mouse tumor allografts were obtained using subcutaneous
injection (s.c.) of 2 × 106 cells in CD1 nude mice (Harlan). Tumors
and organs were fixed in 10% buffered formalin overnight; fixed
tissues were paraffin-embedded, and 5-lm sections were placed on
sialylated/poly-l-lysine slides for further analysis. Tumor burden
was assessed on the hematoxylin and eosin staining (H&E) of the
lungs by two observers, inter-observer agreement quadratic
weighted kappa = 0.79 (good agreement).
Genetically modified mice and animal care
Animals were kept in conventional animal facilities and monitored
daily, and all experiments were carried out in compliance with UK
Home Office guidelines. Mice were genotyped by Transnetyx (Cor-
dova, TN). Mice were treated with 1 mg/kg LOX-blocking antibody
or isotype control antibody in PBS, and/or 100 mg/kg gemcitabine,
twice weekly by i.p. injection. Tumor and metastatic burden was
assessed by gross pathology and histology. Animals were sacrificed
by cervical dislocation as per the institutional guidelines, and organs
and tumors were removed and either fixed in 10% buffered formalin
overnight at room temperature or snap-frozen in liquid nitrogen.
Fixed tissues were paraffin-embedded, and 5-lm sections were
placed on sialynated/poly-l-lysine slides for immunohistochemical
analysis.
Immunohistochemistry
Formalin-fixed paraffin-embedded sections were deparaffinized and
rehydrated by passage through xylene and a graded alcohol series.
Endogenous peroxidase activity was inactivated by treatment with
3% hydrogen peroxide, after which antigen retrieval was
performed by incubation in citrate buffer in a pressure cooker.
Sections were blocked in 5% serum for an hour and then incubated
with primary antibody overnight at 4°C. Primary antibodies used
were anti-CD31 (Abcam) 1:100, anti-MPO (Dako) 1:1,000, anti-F4/
80 (Abcam) 1:100, anti-tenascin (Sigma) 1:2,000, anti-Ki-67
(Vector) 1:200 and anti-cleaved caspase-3 (R&D) 1:800. Sections
were incubated in secondary antibody for 30 min (Vectastain ABC
system) and staining visualized with 3,30-diaminobenzidine
tetrahydrochloride. Sirius red staining was carried out as described
previously.
Supplementary Information for this article is available online:
http://embomolmed.embopress.org
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